Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 95 | BSPED2023 | Next issue

50th Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Manchester, UK
08 Nov 2023 - 10 Nov 2023

Card image cap
The 50th Annual BSPED Meeting will take place at the Midland Hotel, Manchester from 8-10 November 2023.

Poster Presentations

Diabetes 2

Previous section
Diabetes 1
Table of contents
Next section
Gonadal, DSD and Reproduction 1

ea0095p29 | Diabetes 2 | BSPED2023

Introduction of under-fives type 1 diabetes clinic improves glycaemic control through rapid access to automated insulin delivery systems

Balagamage Chamila , Pemberton John , Collins Louise , Krone Ruth

Introduction: Achieving glycaemic targets for young children with type 1 diabetes (T1D) is challenging due to rapidly changing physiology and behavioural patterns. An under-fives specialised multidisciplinary clinic (U5-MDT) was implemented in January 2022 due to poorer glycaemic control in this group compared to the rest of the clinic cohort. The U5-MDT aimed to optimise glycaemic control through access to technology while providing family support.<p clas...
1 shares

ea0095p30 | Diabetes 2 | BSPED2023

Type 1 diabetes in pre-school children: Identifying targets for quality improvement through a countywide review evaluating clinical presentation, management, and outcomes

Dale Jessica

Introduction: Pre-school children with Type 1 Diabetes are a vulnerable group of patients, presenting both diagnostic and management challenges which can place them at increased risk of worse glycaemic control and the complications of Diabetes. The use of advancing diabetes-related technologies including continuous glucose monitoring (CGM) and Hybrid-closed loop (HCL) systems offers the real potential to improve outcomes.Aim:</st...
1 shares

ea0095p31 | Diabetes 2 | BSPED2023

Abstract withdrawn...
0 shares

ea0095p32 | Diabetes 2 | BSPED2023

A new educational tool for prevention of DKA at diagnosis of type 1 diabetes

McGuigan Michael , Bowen Philippa , Metcalfe Carol , Moor Nicky , Morais Marlon , Rowland Charlotte , Shetty Ambika , Nicole Tamsyn , Maiden Jonathan , Savage Emma , Carson Margot

Late diagnosis of type 1 diabetes, leading to diabetic ketoacidosis (DKA) is a significant concern in the UK. The National Paediatric Diabetes Audit 2021/22 showed that 25.6% of children and young people diagnosed with type 1 diabetes in England and Wales presented in DKA, with a rising trend over recent years. Reduction in DKA at diagnosis is part of Aim 1 of the National Children & Young People’s Diabetes Network (NCYPDN) Delivery Plan 2020–25. A working group ...
0 shares

ea0095p33 | Diabetes 2 | BSPED2023

Neonatal diabetes: A challenging case scenario and therapeutic considerations

Sathesh Kumar Sajithbhavan Kuttappan , Stuart Davision , Shaju Edavana , Casey Lambourne , Vicki Brown , Bev Anderson

Neonatal Diabetes: A Challenging Case Scenario and Therapeutic Considerations Neonatal diabetes is a rare form of diabetes mellitus that presents in the first six months of life. This abstract highlights a challenging case scenario of neonatal diabetes and provides insights into the diagnostic approach, therapeutic considerations, and long-term management strategies. The case involves a term male neonate who presented with severe hyperglycemia, polyuria, and failure to thrive....
1 shares

ea0095p34 | Diabetes 2 | BSPED2023

Effect of the T-Slim pump with control IQ hybrid closed loop system on physiological and psychological outcomes in children with type 1 diabetes in gloucestershire

Till Lottie , Cullen Victoria , Balapatabendi Mihirani

Background: In March 2022, NICE guidelines advised that real-time continuous glucose monitoring (rtCGM) be offered to all children and young people with type 1 diabetes mellitus (T1DM). Using rtCGM alongside the hybrid closed loop system (HCLS), has transformed management of T1DM in adults and children alike by linking insulin delivery to sensor glucose levels.Aim: To evaluate how the T-Slim pump with control IQ HCLS aff...
0 shares

ea0095p35 | Diabetes 2 | BSPED2023

Use of sensor augmented pump therapy is safe and effective in patients with significant deprivation and high risk HBA1c

Soo Janet , McCabe Angeline , Smith Paula , Gardner Chris

Background: Advances in insulin pumps and continuous monitoring mean that, where indicated sensor augmented pump therapy (SAPT) can be prescribed for children under NHS care in England. National Paediatric Diabetes Audit (NPDA) data shows improved diabetes outcomes (in terms of HBA1c) in children managing their diabetes in this way. Use of this technology is significantly lower in children in the lower deprivation quintiles and in patients from non white ethni...
0 shares

ea0095p36 | Diabetes 2 | BSPED2023

Abstract withdrawn...
0 shares

ea0095p37 | Diabetes 2 | BSPED2023

Examining the relationship between social deprivation, health outcomes and technology uptake in a district general hospital setting – are we providing equity in our service?

Austreng Lucy , Coxson Edward

Introduction: The International Diabetes Federation 2019 Diabetes Atlas states that the UK has the highest number of children and young people aged 0–14 with Type 1 Diabetes in Europe, with the incidence of cases observed to be rising on a national and international level. The National Paediatric Diabetes Audit (NPDA) 2020–2021 report identified countrywide inequalities between measures of diabetic health and treatment devices used within the paediat...
0 shares

ea0095p38 | Diabetes 2 | BSPED2023

Abstract withdrawn...
0 shares

ea0095p39 | Diabetes 2 | BSPED2023

Right diagnosis, right treatment: Think MODY early in children who present with symptoms of diabetes

Jeyaraman Alagusutha , Khair Mohamed , Jhamba Rumbidzai S

Background: Although it accounts for small number (1–2%) of diabetes cases, MODY is especially important to be picked up by health care providers because of the implications of the correct diagnosis on clinical management and family counselling. MODY should be suspected when a patient <25 years old presents with symptoms of diabetes, who has a family history of diabetes/ MODY, with negative diabetes autoantibodies screen, and/or suboptimal response to...
1 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more